Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
100%(9 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
8
80%
Ph phase_2
2
20%

Phase Distribution

8

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (80.0%)
Phase 22 (20.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

NCT02244463
terminatedphase_1

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

NCT02575339
completedphase_1

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

NCT02719691
completedphase_2

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020
completedphase_1

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02514824
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02244463Phase 1

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Completed
NCT02575339Phase 1

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Terminated
NCT02719691Phase 1

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Completed
NCT02724020Phase 2

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Completed
NCT02514824Phase 1

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Completed
NCT01058707Phase 1

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Completed
NCT02327169Phase 1

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Completed
NCT02091531Phase 2

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Completed
NCT01351350Phase 1

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Completed
NCT01118689Phase 1

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10